Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Sadoff, J., Gars, M. L., Shukarev, G., Heerwegh, D., Truyers, C., Groot, A. M., . . . Schuitemaker, H. (2020). Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: Interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. MedRxiv. doi:10.1101/2020.09.23.20199604
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial
Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants